摘要
目的 探究熊去氧胆酸(UDCA)对原发性胆汁性胆管炎(PBC)患者及其家属严重急性呼吸综合征冠状病毒2(SARSCoV-2)感染症状的影响。方法 通过问卷收集2023年3月22日之前就诊于空军军医大学第一附属医院的PBC患者(n=171)及家属(n=128)的人口学信息、合并症、UDCA用药、SARS-CoV-2感染、疫苗接种、症状特征、治疗用药以及肝病相关症状变化等信息。计量资料两组间比较采用成组t检验或Mann-Whitney U检验。计数资料两组间比较采用χ^(2)检验或Fisher精确检验。结果 PBC患者和家属两组人群的中位年龄为51岁和49岁,差异无统计学意义(P>0.05)。PBC患者的BMI[(22.2±2.4)kg/m^(2)vs (23.3±2.9)kg/m^(2)]和男性比例(10%vs 55%)明显低于家属组(P值均<0.001)。PBC患者均按照13~15 mg/kg服用UDCA,两组SARS-CoV-2感染率均为100%。患者家属的SARS-CoV-2疫苗接种率显著高于PBC患者(91%vs57%,P<0.001)。PBC患者感染SARS-CoV-2后的喷嚏、鼻塞、胸痛以及味觉异常等症状显著轻于患者家属(P值均<0.05)。PBC患者复方感冒药(11%vs 20%)以及连花清瘟胶囊(12%vs 21%)的使用率显著低于患者家属(P值均<0.05)。PBC患者感染SARS-CoV-2后乏力、腹胀、口干眼干、皮肤瘙痒和皮肤黄染等肝病相关症状的加重率分别为37%、2%、27%、10%和3%。结论 与未服用UDCA的PBC直系家属相比,服用UDCA的PBC患者其SARS-CoV-2感染率并未降低,但UDCA可能在减轻患者感染相关症状方面发挥一定的保护作用。PBC患者在感染SARS-CoV-2后仍会出现肝病相关症状的加重,需进一步重视PBC患者SARS-CoV-2感染后的远期影响。
Objective To investigate the effect of ursodeoxycholic acid(UDCA)on the symptoms after severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)infection in patients with primary biliary cholangitis(PBC)and their family member.Methods A questionnaire survey was conducted to collect related information from 171 PBC patients who attended The First Affiliated Hospital of Air Force Medical University before March 22,2023 and 128 family members,including demographic information,comorbidities,UDCA administration,SARS-CoV-2 infection,vaccination,symptoms,therapeutic medication,and the changes in liver disease-related symptoms.The independent-samples t test or the Mann-Whitney U test was used for comparison of continuous data between two groups,and the chi-square test or the Fisher’s exact test was used for comparison of categorical data between two groups.Results The median age was 51 years in the PBC patients and 49 years in the family members,with no significant difference between the two groups(P>0.05).Compared with the family member group,the PBC group had significantly lower body mass index(22.2±2.4 kg/m^(2) vs 23.3±2.9 kg/m^(2),P<0.001)and proportion of male individuals(10%vs 55%,P<0.001).All PBC patients received UDCA at a dose of 13—15 mg/kg,and SARS-CoV-2 infection rate was 100%in both groups.The family members had a significantly higher SARS-CoV-2 vaccination rate than the PBC patients(91%vs 57%,P<0.001).Compared with the family members,the PBC patients had significantly milder symptoms of sneezing,nasal obstruction,chest pain,and abnormal taste(P<0.05).Compared with the family members,the PBC patients had significantly lower rates of use of compound cold medicine(11%vs 20%,P<0.05)and Lianhua Qingwen capsules(12%vs 21%,P<0.05).For the PBC patients after SARS-CoV-2 infection,the liver disease-related symptoms such as fatigue,abdominal distension,dry mouth and dry eyes,pruritus,and yellow skin were aggravated by 37%,2%,27%,10%,and 3%,respectively.Conclusion Compared with the immediate family members of P
作者
贾桂
杨春梅
王秀芳
邓娟
孙瑞青
郑林华
尚玉龙
韩英
JIA Gui;YANG Chunmei;WANG Xiufang;DENG Juan;SUN Ruiqing;ZHENG Linhua;SHANG Yulong;HAN Ying(Department of Gastroenterology,The First Affiliated Hospital of Air Force Medical University,Xi’an 710032,China)
出处
《临床肝胆病杂志》
CAS
北大核心
2024年第7期1370-1374,共5页
Journal of Clinical Hepatology
基金
陕西省重点研发计划(2021ZDLSF02-07)。
